{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"084-113-972-789-703","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"084-113-972-789-703"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10802,"type":"PATENT","title":"Brown University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4664,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8267,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Brown Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2360
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
Search Applicants and Owners separately: \"Brown Univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2360
Search Applicants and Owners separately: Newcastle Univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1333
(i) a polypeptide consisting of a sequence at least 80% identical to amino acids 38-365 of SEQ ID NO: 9, wherein the polypeptide is capable of binding to alpha-sarcoglycan and gamma-sarcoglycan and does not comprise glycosaminoglycan (GAG) side chains; and\n
(ii) a physiologically acceptable carrier or excipient;\n"],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, wherein the polypeptide consists of an amino acid sequence which is at least about 90% identical to amino acids 38-365 of SEQ ID NO: 9."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, wherein the polypeptide consists of an amino acid sequence that is at least about 95% identical to amino acids 38-365 of SEQ ID NO: 9."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, wherein the polypeptide is encoded by a nucleic acid which hybridizes to SEQ ID NO: 8 under stringent conditions of 6.0× sodium chloride/sodium citrate (SSC) at about 45° C. to a complementary strand of SEQ ID NO: 8."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, wherein the polypeptide consists of an amino acid sequence that is at least about 99% identical to amino acids 38-365 of SEQ ID NO: 9."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, which is formulated for injection."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 6, which is formulated for intramuscular injection."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 6, which is formulated for subcutaneous injection."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, which is formulated for systemic administration."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 1, which comprises a suspending, stabilizing, or dispersing agent."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising:\nwherein the composition is formulated as a sterile aqueous solution suitable for systemic administration or injection.\n
(i) a polypeptide consisting of a sequence at least 80% identical to amino acids 20-365 of SEQ ID NO: 9, wherein the polypeptide is capable of binding to alpha-sarcoglycan and gamma-sarcoglycan and does not comprise glycosaminoglycan (GAG) side chains; and\n
(ii) a physiologically acceptable carrier or excipient;\n"],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 11, wherein the polypeptide consists of an amino acid sequence which is at least about 90% identical to amino acids 20-365 of SEQ ID NO: 9."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 11, wherein the polypeptide consists of an amino acid sequence which is at least about 95% identical to amino acids 20-365 of SEQ ID NO: 9."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 11, wherein the polypeptide consists of an amino acid sequence which is at least about 99% identical to amino acids 20-365 of SEQ ID NO: 9."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 11, which is formulated for injection."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 15, which is formulated for intramuscular injection."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 15, which is formulated for subcutaneous injection."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 11, which is formulated for systemic administration."],"number":18,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}wherein the composition is formulated as a sterile aqueous solution suitable for systemic administration or injection.\n